<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03452592</url>
  </required_header>
  <id_info>
    <org_study_id>20180208</org_study_id>
    <nct_id>NCT03452592</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M</brief_title>
  <official_title>Multicenter, Randomized and OpenⅡb Clinical Trials to Evaluate the Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients Harbouring T790M Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allist Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allist Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to evaluate the efficacy and safety of Alflutinib in locally advanced
      or metastatic non-small cell lung cancer patients harbouring T790M mutation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized and open Ⅱb phase study assessing the efficacy and safety
      of Alflutinib at doses of 80 mg orally /once daily and 160 mg orally /once daily in patients
      with locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) harboring acquired
      T790M mutation after EGFR-TKI treatment or primary T790M mutation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate of Alflutinib</measure>
    <time_frame>CT or MRI at screening and every 2 Cycles (from first dose of multiple dosing) until disease progression or withdrawal from study, whichever came first, assessed up to 52 weeks</time_frame>
    <description>Evaluation of the objective response rate of Alflutinib in locally advanced or metastatic non-small cell lung cancer patients harbouring acquired T790M mutation by prior therapy with an EGFR-TKI or primary T790M mutation assessed by RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free disease of Alflutinib</measure>
    <time_frame>CT or MRI at screening and every 2 Cycles (from first dose of multiple dosing) until disease progression or withdrawal from study, whichever came first, assessed up to 52 weeks</time_frame>
    <description>Progression of tumor was assessed by RECIST 1.1 thereby to evaluate progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival of Alflutinib</measure>
    <time_frame>CT or MRI at screening and every 2 Cycles (from first dose of multiple dosing) until disease progression or withdrawal from study, whichever came first, assessed up to 52 weeks</time_frame>
    <description>Evaluation of the overall survival of Alflutinib in locally advanced or metastatic non-small cell lung cancer patients harbouring acquired T790M mutation by prior therapy with an EGFR-TKI or primary T790M mutation assessed by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response of Alflutinib</measure>
    <time_frame>CT or MRI at screening and every 2 Cycles (from first dose of multiple dosing) until disease progression or withdrawal from study, whichever came first, assessed up to 52 weeks</time_frame>
    <description>Evaluation of the duration of response of Alflutinib in locally advanced or metastatic non-small cell lung cancer patients harbouring acquired T790M mutation by prior therapy with an EGFR-TKI or primary T790M mutation assessed by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate of Alflutinib</measure>
    <time_frame>CT or MRI at screening and every 2 Cycles (from first dose of multiple dosing) until disease progression or withdrawal from study, whichever came first, assessed up to 52 weeks</time_frame>
    <description>Progression of tumor was assessed by RECIST 1.1 thereby to evaluate disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit of Alflutinib</measure>
    <time_frame>CT or MRI at screening and every 2 Cycles (from first dose of multiple dosing) until disease progression or withdrawal from study, whichever came first, assessed up to 52 weeks</time_frame>
    <description>Clinical benefit rate was calculated by adding up complete remission, partial remission and stabilization of disease assessed by RECIST 1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Advanced NSCLC Patients With T790M</condition>
  <arm_group>
    <arm_group_label>The way patients take Alflutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients take Alflutinib orally once per day at dose of 80mg or160mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alflutinib</intervention_name>
    <description>Patients take Alflutinib orally once per day at dose of 80 mg or 160 mg</description>
    <arm_group_label>The way patients take Alflutinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Male or female, aged at least 18 years.

          -  2.Histologically or cytologically confirmed, and locally advanced or metastatic NSCLC,
             who are not suitable for surgery /radiotherapy.

          -  3.Patients who have disease progression after continuous previous treatment of
             1st/2nd-generation EGFR TKIs (evaluation according to imaging evidence, judged by
             research center) will be recruited and primary T790M mutation patients are allowed to
             have received no EGFR-targeting therapy before detection.

          -  4.The tissue/cell specimen collected from patients who have received the recent
             treatment (either TKI or chemotherapy) progression should be confirmed to T790M
             positive mutation by the detection of central laboratory, while no specimen collection
             requirements for the primary T790M mutation patients.

          -  5. ECOG performance status of 0 to 2. Life expectancy of at least 12 weeks.

          -  6. At least one measurable lesion by CT or MRI. The measureable lesion should receive
             no local treatments, such as, radiotherapy. If the lesions located at the regions
             which were previously treated are confirmed to progress, they can be chosen as lesion
             according to RECIST Version 1.1.

          -  7. Organ function must meet the following requirements (patients should receive no
             blood transfusion, blood product, hematopoietic stimulating factors, and albumin)：

               -  Absolute neutrophil count &gt;= 1.5 x 109/L, Platelet count &gt;= 75 x109/L,
                  Haemoglobin &gt;= 90 g/L;

               -  Alanine aminotransferase/Aspartate aminotransferase &lt;= 2.5 times the upper limit
                  of normal (ULN) if no demonstrable liver metastases or &lt;= 5 times in the presence
                  of liver metastases;

               -  Total bilirubin &lt;= 1.5 times ULN if no liver metastases or &lt;= 3 times ULN in the
                  presence of liver metastases;

               -  Creatinine &lt;=1.5 times ULN concurrent with creatinine clearance &gt;= 50 ml/min
                  (measured or calculated by Cockcroft and Gault equation);

          -  8. Females who have fertility potential before menopause should have a pregnancy test
             in the time period of 7 days prior to start of dosing, should not be breast feeding
             and must have a negative pregnancy test (blood test or urinalysis) prior to start of
             dosing; all enrolled patients should take the barrier contraceptive methods during the
             therapy and three months after therapy

          -  9. Patients are volunteered to enroll and sign a written informed consent form, and
             they can follow the therapeutic schedule and visit plan.

        Exclusion Criteria:

          -  1. Previous treatment as follows: Patients received any cytotoxic chemotherapy or
             immunotherapy (such as, PD-1 antibody, PD-L1antibody) from a previous treatment
             regimen or clinical study within 21 days prior to study entry; The time from stopping
             taking any target cancer drug of a previous treatment to study entry is less than its
             5x half-life (such as, the time for erlotinib is less than 8 days, the time for
             gefinitib is less than 10 days, the time for icotinib is less than 2 days, the time
             for afatinib is less than 8 days ); The time from stopping taking any studied drug or
             anti-cancer drug of a previous treatment to study entry is less than its 5x half-life;
             Patients performed on major surgery within 4 weeks prior to study entry (excluding
             from and vascular passage-rebuilt surgery and biopsy operation); Patients performed on
             more than 30% of bone marrow radiotherapy or large area irradiation

          -  2. Patients previously treated by 3nd-generation EGFR-TKI , analogous drug (such as
             Osimertinib (Tagrisso®, AZD9291), Rociletinib (CO-1686), Olmutinib (Olita®,HM61713),
             ASP8273, EGF816, HS-1029, and avitinib), or their bulk drugs and generic drug。

          -  3. Patients were taking and could not stop the drugs within 2 weeks prior to study
             entry. The drugs are as following:

               -  Potent inhibitors or inducers of CYP3A4;

               -  Traditional Chinese medicine and preparations whose therapeutic goal is
                  anti-tumors；Antitumor adjuvant therapy of Traditional Chinese medicine and
                  preparations; Drugs with antitumor activity for patients judged by investigator.

          -  4. Unrecovered toxic reaction due to former therapy existed, with over 1 grade of
             CTCAE (except alopecia) or 2 grade if ever applied DDP curing related neuropathy.

          -  5. Spinal compression, or brain metastasis exhibiting symptoms but untreated (except
             those exhibit no symptom with stable condition and do not apply corticosteroids for 4
             weeks before the trail initiating)

          -  6. Any evidence showing severe or inadequate controlled systemic disease. For example
             patients with inadequate controlled hypertension considered not suitable for the trail
             or would affect the compliance towards the protocol, with active hemorrhagic tendency,
             with active infection such as HBV (HBV-DNA≥1000cps/ml), with HCV, with HIV et al
             (except for HBV carrier those the researcher considered meet the criterion).

          -  7. Any condition affecting the drug taking, or significantly affecting the absorption
             or the pharmacokinetic parameters, include any kind of uncontrollable nausea or vomit,
             chronic gastroenteropathy, disability in swallowing, and history of gastrointestinal
             resection or surgery.

          -  8. Any condition meet the following cardiac standard: ECG show a QTc&gt;470 msec under
             resting state (Repeat in 48 hours when a first abnormal discovered, take mean of the
             two measurements). All kinds of abnormal in cardiac rhythm, conduction and resting ECG
             profile with clinical significance, for example complete left bundle branch block, 2
             or 3 grade of conduction block and a PR interval&gt;250 msec. Any possible factors
             increasing the risk of QTc extending or leading to arrhythmia, such as heart failure,
             hypokalemia, congenital long QT syndrome, any first degree relative suffered from long
             QT syndrome or undertook unexplained sudden death before 40 years old, or taking any
             drug leading to a longer QTc.

          -  9. Echocardiographic examination: LVEF&lt;50%

          -  10. Any history of interstitial lung disease, drug induced interstitial lung disease,
             radiation pneumonia require steroid therapy or active interstitial lung disease with
             clinical evidence during recruiting.

          -  11. Lung functional examination: FEV1/FVC&lt;70%, and FEV1&lt;30%, or (DLCO%) &lt; 40%.

          -  12.Patients with acute onset or ongoing, pulmonary symptoms and interstitial lung
             disease that the researchers considered not suitable for trail.

          -  13. Patients with other factors the researchers considered not suitable for the trail
             (for example, patients those who not willing to follow the procedure, limitation or
             requirements, who once experienced bone marrow allotransplantation, who have other
             kinds of malignant tumor coexisted or who showed allergic to the active ingredients or
             inactive adjuvant of the investigational drug, as well as drugs with similar chemical
             structure or in the same class).

          -  14. Confirmed mutation of EGFR 20 exon insertion at anytime after the first diagnosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>February 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2018</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

